Bevacizumab (Avastin)
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Breast cancer
- Cervical cancer
- Colon cancer
- Esophageal cancer
- Hepatobiliary cancer
- Non-small cell lung cancer
- Ovarian cancer
- Renal cancer
- Unknown primary
Information about counterfeit Bevacizumab (Avastin)
- FDA's 2/14/2012 statement about counterfeit Avastin in U.S.
- Genentech's 2/14/2012 statement on counterfeit drug labeled as Avastin (Bevacizumab) in the United States - contains pictures of authentic and counterfeit product
- Authorized specialty distributors, wholesalers and specialty pharmacies for Bevacizumab (Avastin)
Patient drug information
- Bevacizumab (Avastin) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on pages 22-23 of the package insert[1]
- Bevacizumab (Avastin) patient drug information (UpToDate)[5]
References
Categories:
- Drug index
- Chemotherapy
- Antibody medications
- VEGF inhibitors
- Breast cancer medications
- Cervical cancer medications
- Colon cancer medications
- Esophageal cancer medications
- Hepatobiliary cancer medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Renal cancer medications
- Cancer of unknown primary medications